delta9-tetrahydrocannabinol/cannabidiol combination agent

{
  "id": "MLC-T-ONC-012957",
  "term": "delta9-tetrahydrocannabinol/cannabidiol combination agent",
  "field": "Oncology and biomedicine",
  "definition": "A sub-micron spray containing a nanoparticle water soluble equimolar solution composed of delta-9-tetrahydrocannabinol (delta-9-THC; d9-THC), an analogue of tetrahydrocannabinol (THC) and the primary form of THC found in the Cannabis sativa L. plant, and cannabidiol (CBD), a phytocannabinoid derived from Cannabis species, with potential analgesic activity. Upon administration to the oro-buccal membrane, d9-THC/CBD combination agent binds to and activates the cannabinoid G-protein coupled receptor (CBR) located in the central nervous system (CNS). This activates the inwardly rectifying potassium channels, which decrease presynaptic neuron firing, and inhibits voltage-sensitive calcium channels that decrease neurotransmitter release. This inhibits excitatory postsynaptic neuronal transmission, and inhibits the release of pro-inflammatory mediators. This provides an analgesic effect.",
  "synonyms": [
    "d9-THC/CBD nanoparticle-based combination agent"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/delta9-tetrahydrocannabinol-cannabidiol-combination-agent/"
}